1.4 Evolution in medical treatment
By providing inexpensive, high-quality biosimilars and “authorized versions” of biologics, we will contribute to the further use of biomedicines, and help increase healthcare spending, which is a global issue.
- We will proceed with the development of biosimilars, aim to quickly obtain manufacturing and marketing approval, and begin sales.
- We will establish a new company with the aim of obtaining manufacturing and marketing approval in Japan for an authorized version of NESP®.
1) Acquire approval for biosimilars in accordance with the patent regulations in each country and region and begin sales.
2) Acquire approval for NESP® authorized generics
Goals for 2021
1) Achieve in 2018
2) Achieve in 2018
Evolution in medical treatment
We will contribute to reducing healthcare spending through the increased use of inexpensive, high quality biomedicines.
Developing unique pharmaceuticals to bring relief to patients around the world
In accordance with its CSV Commitment in the ﬁeld of health and well-being, the Kirin Group is working to continuously create ground-breaking new drugs and promote advancements in medical treatments. In line with that commitment, Kyowa Kirin has set the goal of marketing at least three new independently developed pharmaceutical products in over 50 countries.
Improving quality of life of patients around the world
The corporate philosophy of Kyowa Kirin, which conducts the Kirin Group’s medical business, is to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. Under this philosophy,we are focusing research and development efforts on the four key areas of nephrology,oncology, immunology/allergy, and the central nervous system leveraging our cutting-edge biotechnology anchored in antibody technology.